Wednesday, March 22, 2017

BioClin Therapeutics Takes $30M

San Ramon-based BioClin Therapeutics, a drug development company focused on treating metastatic cancer, has raised $30M in a Series B funding, the company announced this morning. The funding was led by Sofinnova Ventures and Ysios Capital, and also included HealthCap, Life Sciences Partners (LSP), and Tekla Capital Management. The company has now raised $59M in total. BioClin said it will use the funding to advance its development of a anti-FGFR3 (fibroblast growth factor receptor 3) monoclonal antibody specifically aimed at treating metastatic bladder cancer. Cory Freedland of Sofinnova Ventures and Joel Jean-Mairet of Ysios Capital have both joined the company's board, with David Lacey joining as a Board Observer.